PSP Research LLC Purchases New Shares in Dianthus Therapeutics, Inc. $DNTH

PSP Research LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,725 shares of the company’s stock, valued at approximately $524,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fairmount Funds Management LLC grew its position in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after buying an additional 600,000 shares during the period. Vestal Point Capital LP grew its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares during the period. Wellington Management Group LLP grew its position in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares during the period. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC grew its position in shares of Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 114,367 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The SEC filing for this sale provides additional information. In the last three months, insiders sold 323,021 shares of company stock valued at $26,564,008. Corporate insiders own 3.02% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on DNTH shares. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Trading Up 2.5%

NASDAQ:DNTH opened at $85.67 on Wednesday. The company’s 50-day moving average price is $85.55 and its 200-day moving average price is $59.22. The company has a market cap of $4.68 billion, a P/E ratio of -20.74 and a beta of 1.18. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. On average, analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.